

CLINICAL TRIAL

PAROS - NCT02771379



Neuroophthalmology RED

A Phase 3 Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of Emixustat Hydrochloride With Placebo for the Treatment of Macular Atrophy Secondary to Stargardt Disease

Rare Eye Disease concerned by the trial :
Leber hereditary optic neuropathy (LHON)

Status of the trial : Active, not recruiting
Orphan drug recognition : Yes

Inclusion criteria : [Click here to see detailed criteria](#)

Exclusion criteria : [Click here to see detailed criteria](#)



Inclusion
opening date : 2019



Inclusion closing
date (previsional) : 2021

Children



Adults



Within ERN-EYE members



Locations of the trial :

Hôpital européen Georges-Pompidou AP-HP
Paris, France

Rigshospitalet - Glostrup
Valdemar Hansens Vej 1, Glostrup, Denmark


Universitätsklinikum Tübingen
Tübingen, Germany

Azienda Ospedaliero Universitaria Careggi
Florence, Italy, 50124

Radboud University Medical Center,
Nijmegen, Netherlands

Oxford University Hospitals NHS Foundation Trust,
Oxford, UK

Moorfields Eye Hospital
London, United Kingdom, EC1V 2PD



Funder type : Industry

[More informations](#)